150 related articles for article (PubMed ID: 17867605)
1. [Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].
Gattenlöhner S
Verh Dtsch Ges Pathol; 2006; 90():264-76. PubMed ID: 17867605
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor.
Gattenlöhner S; Marx A; Markfort B; Pscherer S; Landmeier S; Juergens H; Müller-Hermelink HK; Matthews I; Beeson D; Vincent A; Rossig C
Cancer Res; 2006 Jan; 66(1):24-8. PubMed ID: 16397210
[TBL] [Abstract][Full Text] [Related]
3. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.
Gattenloehner S; Vincent A; Leuschner I; Tzartos S; Müller-Hermelink HK; Kirchner T; Marx A
Am J Pathol; 1998 Feb; 152(2):437-44. PubMed ID: 9466570
[TBL] [Abstract][Full Text] [Related]
4. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
5. A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.
Gattenloehner S; Dockhorn-Dworniczak B; Leuschner I; Vincent A; Müller-Hermelink HK; Marx A
J Mol Diagn; 1999 Nov; 1(1):23-31. PubMed ID: 11272905
[TBL] [Abstract][Full Text] [Related]
6. Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.
Simon-Keller K; Barth S; Vincent A; Marx A
Expert Opin Ther Targets; 2013 Feb; 17(2):127-38. PubMed ID: 23231343
[TBL] [Abstract][Full Text] [Related]
7. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
Rodeberg DA; Erskine C; Celis E
J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
Tanzarella S; Lionello I; Valentinis B; Russo V; Lollini PL; Traversari C
Cancer Immunol Immunother; 2004 Jun; 53(6):519-24. PubMed ID: 14727086
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive T-cell therapy of rhabdomyosarcoma].
Simon-Keller K; Paschen A; Eichmüller S; Gattenlöhner S; Barth S; Koscielniak E; Leuschner I; Stöbel P; Hombach A; Abken H; Marx A
Pathologe; 2010 Oct; 31 Suppl 2():215-20. PubMed ID: 20730458
[TBL] [Abstract][Full Text] [Related]
10. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.
Simon-Keller K; Paschen A; Hombach AA; Ströbel P; Coindre JM; Eichmüller SB; Vincent A; Gattenlöhner S; Hoppe F; Leuschner I; Stegmaier S; Koscielniak E; Leverkus M; Altieri DC; Abken H; Marx A
Am J Pathol; 2013 Jun; 182(6):2121-31. PubMed ID: 23562272
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of the transcription of the fetal type acetylcholine receptor and myogenin in rhabdomyosarcoma].
Gattenlöhner S; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 1998; 82():195-201. PubMed ID: 10095433
[TBL] [Abstract][Full Text] [Related]
12. A new marker for rhabdomyosarcoma. Insulin-like growth factor II.
Yun K
Lab Invest; 1992 Nov; 67(5):653-64. PubMed ID: 1434543
[TBL] [Abstract][Full Text] [Related]
13. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
14. The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: diagnostic and prognostic utility.
Wijnaendts LC; van der Linden JC; van Unnik AJ; Delemarre JF; Voute PA; Meijer CJ
J Pathol; 1994 Dec; 174(4):283-92. PubMed ID: 7884590
[TBL] [Abstract][Full Text] [Related]
15. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis.
Coffin CM; Rulon J; Smith L; Bruggers C; White FV
Mod Pathol; 1997 Dec; 10(12):1175-87. PubMed ID: 9436961
[TBL] [Abstract][Full Text] [Related]
16. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
Heuser C; Hombach A; Lösch C; Manista K; Abken H
Gene Ther; 2003 Aug; 10(17):1408-19. PubMed ID: 12900755
[TBL] [Abstract][Full Text] [Related]
17. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
Turatti F; Figini M; Balladore E; Alberti P; Casalini P; Marks JD; Canevari S; Mezzanzanica D
J Immunother; 2007 Oct; 30(7):684-93. PubMed ID: 17893561
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
19. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.
Melguizo C; Prados J; Marchal JA; Vélez C; Carrillo E; Boulaiz H; Sánchez-Montesinos I; Madeddu R; Aránega A
Neoplasma; 2003; 50(2):91-6. PubMed ID: 12740641
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells.
Ricaud S; Vernus B; Duclos M; Bernardi H; Ritvos O; Carnac G; Bonnieu A
Oncogene; 2003 Nov; 22(51):8221-32. PubMed ID: 14614446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
